The Medical Letter on Drugs and Therapeutics
In Brief: Hepatitis B Reactivation with Direct-Acting Antiviral Drugs for Hepatitis C
Download PDF:   US English
Med Lett Drugs Ther. 2016 Oct 24;58(1506):140
 Select a term to see related articles  daclatasvir   Daklinza   dasabuvir   elbasvir   Epclusa   Galexos   grazoprevir   Harvoni   hepatitis b   Hepatitis C   Holkira Pak   ledipasvir   Olysio   ombitasvir   paritaprevir   Ritonavir   simeprevir   sofosbuvir   Sovaldi   Technivie   velpatasvir   Viekira Pak   Zepatier 

The FDA recently announced that it will require the labeling of all direct-acting antiviral drugs used for treatment of hepatitis C virus (HCV) infection to include a boxed warning about a risk of hepatitis B virus (HBV) reactivation associated with their use.1

Twenty-four cases of HBV reactivation occurring during treatment with direct-acting antiviral drugs for HCV were identified from the FDA Adverse Event Reporting System and the medical literature.2-5 Before starting direct-acting antiviral treatment for HCV, some of these patients were hepatitis B surface antigen (HbsAG) positive and others showed evidence of resolved HBV infection. HBV reactivation generally occurred within 4-8 weeks of starting treatment. Reactivation of HBV can cause increases in bilirubin and aminotransferase levels, fulminant hepatitis, hepatic failure, and death. Of the 24 patients, two died and one required a liver transplant.

HBV reactivation was not identified before FDA approval of these drugs because the clinical trials used to support their approval excluded patients with HBV co-infection. The mechanism by which HBV reactivation occurs during treatment with direct-acting antiviral drugs for HCV is unknown. Patients should be screened for current or past HBV infection before starting treatment with a direct-acting antiviral and monitored for HBV reactivation during and following treatment with these drugs.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article